Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Iain Chapple, University of Birmingham, England, presented the oral session "Longitudinal Serological and Vaccination Responses to SARS-COV-2 in Dental Professionals" at the virtual 99th General Session & Exhibition of the International Association for Dental Research (IADR), held in conjunction with the 50th Annual Meeting of the American Association for Dental Research (AADR) and the 45th Annual Meeting of the Canadian Association for Dental Research (CADR), on July 21-24, 2021.

23 Jul 2021

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

A new study characterizes the functional humoral immunity post-COVID-19 mRNA-based vaccination.

22 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

Innovative testing platform could enable more precise, personalized immunotherapy

An innovative testing platform that more closely mimics what cancer encounters in the body may allow for more precise, personalized therapies by enabling the rapid study of multiple therapeutic combinations against tumor cells.

22 Jul 2021

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Scientists have developed a 'nanobody' - a small fragment of a llama antibody - that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system.

22 Jul 2021

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).

22 Jul 2021

Clinical trial to test personalized treatment for severe asthma caused by a specific mutation

Under a $10 million grant, a randomized, placebo-controlled clinical trial led by Boston Children's Hospital will test a personalized treatment for a form of severe asthma to which Black and Latinx children and adults are especially vulnerable.

21 Jul 2021

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Researchers in the United States have conducted a study showing that while variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can compromise the effectiveness of single therapeutic antibodies at preventing severe coronavirus disease 2019 (COVID-19), many combination antibody products remain potent against the variants.

21 Jul 2021

Older people appear to have diminished antibody response after COVID-19 vaccination

Older people appear to have fewer antibodies against the novel coronavirus, a new laboratory study from Oregon Health & Science University suggests.

21 Jul 2021

Scientists seek to block pathogen’s most reliable weapon to cause severe malaria

The parasites that cause severe malaria are well-known for the sinister ways they infect humans, but new research may lead to drugs that could block one of their most reliable weapons: interference with the immune response.

21 Jul 2021

Analysis: Necessary or not, covid booster shots are probably on the horizon

The drugmaker Pfizer recently announced that vaccinated people are likely to need a booster shot to be effectively protected against new variants of covid-19 and that the company would apply for Food and Drug Administration emergency use authorization for the shot.

21 Jul 2021

Potent nasal vaccine protects non-human primates from SARS-CoV-2

A team of US-based scientists has recently demonstrated the efficacy of a live attenuated, recombinant coronavirus disease 2019 (COVID-19) vaccine candidate currently under phase I clinical trial as a single-dose intranasal vaccine.

20 Jul 2021

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

Florida International University researchers have investigated the mutation-induced structural changes in the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could contribute to its immune evasion abilities.

20 Jul 2021

New study disproves suspicion that dengue raises risk of zika-related microcephaly

A pregnant woman infected by zika virus does not face a greater risk of giving birth to a baby with microcephaly if she has previously been exposed to dengue virus, according to a Brazilian study that compared data for pregnant women in Rio de Janeiro and Manaus.

20 Jul 2021

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Researchers in Canada have developed an adenoviral vector-based vaccine against coronavirus disease 2019 (COVID-19) that induced robust immune protection against the ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice.

20 Jul 2021

Study examines clinical outcomes in vaccinated individuals hospitalized with SARS-CoV-2 Delta variant

A new study has been published on the medRxiv* preprint server that has evaluated the clinical outcomes of the COVID-19 patients hospitalized in AIG hospitals, Hyderabad, India, between April 24, 2021, and May 31, 2021.

20 Jul 2021

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.

20 Jul 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

An interesting new study reports that vaccine hesitancy in the UK is driven not, as is commonly thought, by the so-called ‘infodemic’ of misinformation that has characterized much public messaging during the COVID-19 pandemic. Instead, the personality of the individual, the ability to trust scientific and government leadership, political affiliations, and openness relative to the process of vaccine development was found to be key in the development of this attitude.

20 Jul 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Antibody News and Research

Further Reading

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Innovative testing platform could enable more precise, personalized immunotherapy

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

Clinical trial to test personalized treatment for severe asthma caused by a specific mutation

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Older people appear to have diminished antibody response after COVID-19 vaccination

Scientists seek to block pathogen’s most reliable weapon to cause severe malaria

Analysis: Necessary or not, covid booster shots are probably on the horizon

Potent nasal vaccine protects non-human primates from SARS-CoV-2

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

New study disproves suspicion that dengue raises risk of zika-related microcephaly

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Study examines clinical outcomes in vaccinated individuals hospitalized with SARS-CoV-2 Delta variant

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo